Download
welcome n.
Skip this Video
Loading SlideShow in 5 Seconds..
WELCOME! PowerPoint Presentation

WELCOME!

98 Views Download Presentation
Download Presentation

WELCOME!

- - - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript

  1. WELCOME! European Strategy Meeting October 27-28, 2008

  2. Introductions • Name • Organisation • Country • One thing we wouldn’t know about you, just by looking at you… • A few points about logistics…

  3. Goals of the meeting • Increase our knowledge of key developments and current challenges in the field • Propose strategic directions for microbicides advocacy in Europe • Share our lessons learned, strategies, successes and challenges with our colleagues

  4. Agenda: Day 1 • Introductions • Review key outcomes and follow-up since last year • Overview of HIV prevention landscape • Share achievements and challenges • Hear about community experience in trials • Begin to look at new advocacy goals

  5. Agenda: Day 2 • Learn about resources at our disposal • Learn about rectal microbicides • Review new advocacy objectives • Discuss strategy and priorities for Europe • Develop concrete next steps • Discuss outreach to key constituents

  6. Outcomes from last year&Progress since then

  7. Copenhagen 2007 • Overview of state of the field • “Scenario planning” for future trial results, “strawman” exercise • Setting European advocacy goals • Discussing the relationship between GCM and its “partners” • Discussing next steps • All of this was part of and fed into GCM’s Strategic Review Process

  8. Copenhagen 2007: Setting Goals for Europe • Resource mobilisation • R&D for both VMs and RMs • Social science research • Advocacy and community mobilisation • Advocating for appropriate and supportive policies • Engaging with key constituents • African communities in Europe • HIV+ women • Gay men

  9. Copenhagen 2007: Next Steps • Prepare for Carraguard results • Mapping of European scientists • Consultation on FP7 and EDCTP • Funding for “missing pieces” • National level advocacy • North-South dialogue • Exhibit tour • Spreading the message

  10. Since last year… • Completed SRP (more in a moment) • Carraguard results came out • Mapping of scientists has started • New plan for funding “missing pieces” • National level advocacy continues • Exhibit still available • North-South dialogue • For more info: check out the newsletters!

  11. Partner activities 2007-8… • Events on microbicides • in Belgium, France, UK, Spain, the Netherlands, Finland • Lobbying efforts and Parliamentary events • in Spain, UK, Finland, France, Brussels • Articles on microbicides published in NGO newsletters • in Germany, UK, Spain, France • Presenting at conferences

  12. EU policy and advocacy • Tracking of microbicides policy (development, research, health) • Participation in conferences • Policy meetings with IPM, IAVI and Stop AIDS Alliance • Meetings with policy staff, MEPs, Perm Reps

  13. Training and capacity building • Trainings • UK, Belgium, France, Netherlands, Spain, EATG, Countdown 2015, youth advocates • Presentations and workshops at conferences • AIDS Impact, M2008, AIDS2008 • Site visits • Belgium, France, Spain, Netherlands, Finland • Conference calls • Articles, materials, resources (more tomorrow!) • Outreach and support in 11 countries

  14. European Tour of the Exhibit • AIDS Impact, Marseilles • Finland: Ministry of Foreign Affairs, 3 universities and Parliament House • Global Consultation on SRHR of PLHIV in Amsterdam

  15. For more information…

  16. Key Outcomes from SRP & The Changing Field European Strategy Meeting 27 October 2008

  17. The Global Campaign for Microbicides works to: • Ensure that as science proceeds, public and community interests are fully protected --Accountability • Mobilise demand and investment forresearch and development of new prevention technologies • Conduct policy advocacy for development, testing, access, and use

  18. Role of GCM in Microbicide Landscape • We build capacity for authentic civil society engagement in the scientific process • We advance user and community perspectives • We build grassroots and political support for the long term • We are independent and non-aligned with any product or sponsor

  19. Three-fold objectives • Instrumental – get a product • Strengthen Movements– encourage cross movement linkages; build civil society capacity • Transform Science – forge a new model for doing ethical research in partnership with community

  20. “The way the Campaign is structured is one of its strengths.” In their own words… “GCM is the “go to” organisation for resources, turning that language into understandable information…” “GCM’s continuous vocalising of the need has had enormous repercussions for funding” “[GCM has contributed by] incorporating a user perspective throughout the research process, mobilising resources.., assuring the ethical conduct of research, and ultimately access…” “GCM could improve in sharing resources, especially funding…” “[Without GCM] we would not have gotten this far. We would have been slower in mobilising political support.” “They could and should stay focused on vaginal science, women initiated prevention options” “No other organisation is so connected to the concerns of women, communities, the whole ethics question…”

  21. GCM’s Impact • Generating increased public support and funding in the Global North • Changing the way clinical trials are done • Creating an enabling environment for product development • Fostering a bigger, louder, more empowered grassroots constituency • Bridging science and community

  22. Scope & Mission • Re-focus mission on women’s prevention needs • Maintain leadership on microbicides but expand into PrEP and other tools as they affectwomen • Help co-create larger prevention research field; provide much needed gender expertise • Step up advocacy for access to existing prevention tools and strategies

  23. Female and male condoms, clean needles, male circumcision, VCT Prevention & Testing Deliver today Develop for tomorrow Treatment Trials Towards universal access Vaginal and rectal microbicides, PrEP, vaccines… Integrated View of Prevention

  24. Microbicides Cervical Barriers: vaginal diaphragms Male circumcision Behavioural Intervention (ABC) Exposure prophylaxis PMTCT PEP PrEP Immunisation:Vaccines HSV-2 Suppressive therapy STI Treatment Strategies Voluntary Counseling & Testing Male and Female Condoms HIV PREVENTION 24

  25. Perceived Niche and Reputation • “Honest broker” between community/ civil society and researchers • Voice for users, trial participants, communities and civil society • Some criticism that GCM is too cozy with researchers • Evidence-based, balanced – “doesn’t sell its soul to either side”

  26. Defining CGM’s ComparativeAdvantage • Can bring SRHR and women’s groups to the table • Strong network in Europe • Capacity to “hit the ground running” • Established organisational track record

  27. Strategic Review:Take Home Messages • GCM is taking on the right issues and pursuing broadly supported strategies • People can clearly articulate our objectives • GCM fills crucial roles • Organising (the invisible work) • Bridging and enabling • Timely and trusted communication (cellulose sulfate trials) • Need to strengthen our relationships with advocates, civil society groups and trial staff in key African countries hosting trials

  28. BREAK! • Write down one achievement from last year on a sticky note • Add it to the Wall of Success

  29. The HIV prevention landscape &Europe’s current engagement

  30. HIV/AIDS Toolkit • Education & behaviour change • Male and female condoms • Anti-retroviral therapy (mother-to-child) • Post exposure prophylaxis (PEP) • Anti-retroviral therapy • Care • Education & Behavioural change Prior to exposure Point of transmission After infection • Male circumcision • Preventive Vaccines • Pre-exposure prophylaxis (PrEP) • HSV-2 suppression • TherapeuticVaccines • Vaginal and rectal Microbicides • Diaphragm, cervical barriers & new FCs

  31. Female Barrier - Diaphragm HSV-2 Treatment - Infectiousness Microbicides - Carraguard Oral PrEP - IDU Vaccines - Adenovirus1 Adenovirus 2 Male Circumcision - Susceptibility Community VCT and HIV Support Vaccines - Prime/Boost • Microbicides • BG/Pro2000 • CS – 1 • CS – 2 • Pro2000 • TDF Male Circumcision - Infectiousness HSV-2 Treatment – Susceptibility • Oral PrEP • MSM • Heterosexual Index Partner Treatment Oral PrEP - West Africa 2012 2010 2006 2008 2009 2007 Research that Could Redefine Prevention, 9/06 See also http://www.avac.org/timeline-website/index.htm

  32. Research That Is Redefining Prevention, 10/08 Vaccine – Merck Adeno x2 STEP/Phambili • Oral PrEP • Heterosexual (FemPrEP & Partners) Female Barrier Diaphragm ` Vaccines – Thai Prime/Boost Microbicides – Carraguard Vaginal & Oral PrEP (VOICE) HSV-2 Treatment – Infectiousness • Microbicides • TDF/PMPA (CAPRISA) Microbicides – CS-1 CS-2 Community VCT and HIV Support Male Circumcision – Susceptibility Vaccine – VRC PAVE 100 Oral PrEP – IDU/Thai • Oral PrEP • MSM (iPrEx) • Heterosexual (Botswana) Male Circumcision – Infectiousness HSV-2 Treatment – Susceptibility Index Partner Treatment • Microbicides • BG/Pro2000 • Pro2000 Oral PrEP – West Africa 2011++ 2010 2006 2008 2009 2007 See also http://www.avac.org/timeline-website/index.htm

  33. QUIZ TIME!

  34. QUIZ QUESTION Which European country is the largest donor to microbicides research?

  35. EU Member States Donors = NORWAYSWEDEN DENMARK N’LANDS IRELANDUK BELGIUM GERMANYFRANCE SPAIN Targets = FINLAND ITALY?

  36. European Funding • Increase from 0.5m euros in 2000 to 40.3m euros in 2007 • EU member states have given IPM 71m euros • UK has given over 75m euros • The Netherlands and Ireland are the largest contributors per capita

  37. QUIZ QUESTION What are the major European projects on microbicides?

  38. European Microbicide Research

  39. Mapping of scientists • BELGIUM Balzarini, de Haard, Jespers, Leroux-Roels, Schols, van Roey, van der Mooter, Vanham, Voss • DENMARK Schooler, Pederson • FINLAND ???

  40. Mapping of scientists • FRANCE Le Grand, Martin, Bomsel, Belec, Vita, Rey, Tangy, Verrier, Moog, Canard, Allaire, Storer, Delaporte, Katlama, Paicheler?  • GERMANY Meurer? • IRELAND ???

  41. Mapping of scientists • ITALY Pozzi, Poli, Tagliabue • THE NETHERLANDS Van der Wijgert, Meloen, Schuitemaker? • PORTUGAL ???

  42. Mapping of scientists • SPAIN ??? • SWEDEN Wigzell, Wharen, Chiodl, Spetz, Biberfeld, Thorstensson, Fenyo, Nihlmark • SWITZERLAND Hartley

  43. Mapping of scientists • UK • Kelly, Shattock, McCormack, Lacey, Fletcher, Herrera, Staphanidou • OTHERS?

  44. Mapping of Scientists Time for homework!

  45. Achievements

  46. TIME FOR LUNCH!

  47. The Expanding NPT Universe and how GCM relates to it European Strategy Meeting 27 October 2008

  48. New Areas for Action: • Female Condoms (what can we do now?) • Circumcision (what does it mean for women?) • ARV-Based Prevention = • Treatment as prevention • PPTCT • PrEP • ARV-based microbicides